Member Info for TorquayFan

. . .that should be, SCIB1 Phase 1 and 2 trial results !

I always enjoy your posts and Fri 16.04 is no exception . . . just to note, there's a lot of 'hoping' in there and why not ? I guess that's why we bought the share ! We can see Scancell's potential and have faith . . . .

When you look at the SCIB1/2 trial results, 'way above the norm' or something that Keith Flaherty said, the enthusiasm of CRUK for SCIB1 and more, the trail of Patents and interest in Prof. Lindy's work from BioNTech/Genentech etc., the SP is plain crazy.

I expect early news from the FDA re. SCIB1 Combo, more Patent news and a good GC result. When the trials start to progress, hopefully, sentiment will change for the better.

Nice weekend.

Berm posted this Symosium in May 2019 - Prof. Lindy is presenting . .

https://www.icvis.org.uk/

Interesting in view of Scancell's long-standing co-operation with Karolinska . . . .

BioNTech have learnt something interesting from Scancell and Karolinska themselves ?

https://scrip.pharmaintelligence.informa.com/SC124249/BioNTech-CBO-Outlines-Infectious-Disease-Ambitions?

Moljen spot on. BoD ? It seems if a Company hasn't got a message of Scancell's immense strength, it's easy to get Investors to look at prospects and potential, but if a Company has an overwhelming message of amazing science, it's down to the pits ! Shocking.

Crumbs - 20.34, 20.49, 21.05. Great posts. thanks.

Hi TommyF and I must agree just this once with C7 - if Scancell should win an award from the CRUK Grand Challenge - it will be quite significant. It's certain there will be publicity and GREAT publicity IMO. Hopefully that will help change the sentiment on the SCLP project and that should reflect in the SP. It's gonna help the SP - if we win !
And before that - maybe we'll have IND clearance and ?

Bobbust 09.37 - nicely put. Thanks.

Here's another Conference coming up - not for us of course.

https://car-tcongresseu.com/events/car-t-congress-eu-2019?afid

Trying to reduce the costs of Car-T therapy in the EU and looking for alternatives . . . .

https://pharmaphorum.com/top-stories/novartis-focusing-on-cutting-car-t-costs-ahead-of-eu-launches/

There's an ESMO Immuno-Oncology Congress in Geneva, Dec13-16th asmentioned here before.

https://www.esmo.org/Conferences
https://cslide.ctimeetingtech.com/immuno2018/attendee/confcal/presentation

Prof. Melief of ISA and Prof. De Vries from our Grand Challenge team are presenting. Also noticed J.Wargo. It looks like a heavyweight Congress - perhaps BoD will tell us again if SCancell are attending at all.

RW yes indeed it could be . . . it's nice to see these snippets.

My guess is our next news items will be FDA approval of the IND submission - (maybe just a few weeks to wait), Patent announcement - (if I dare mention), followed by the CRUK Grand Challenge result. And anything of a 'left field' from China or other monetization nature to boot !

DA - off topic - surely not. N.B. I didn't mention the 'B' word !

C7 - right on. Just testing - however ''not a mention of Scancell'' IS quite correct.

BioNTech - well spotted !

I wonder when we might hear of CRUK's progress with SCIB2 ? Meantime, Pharmphorum - sorry if this has been posted before :-

''NICE has said MSD’s cancer immunotherapy, Keytruda, should receive interim funding on the NHS in certain patients with untreated lung cancer, in combination with chemotherapy. . . . . . NICE estimates that more than 3,000 patients in England will be eligible for the treatment, made by Merck Sharp and Dohme, known as Merck & Co in the US.''

''Another option for first line lung cancer is Keytruda alone; this option was approved by NICE for routine NHS use in June''

https://pharmaphorum.com/news/thousands-to-benefit-as-nhs-funds-keytruda-lung-cancer-combo/?

Thanks C7 - many reasons to be cheerful of course.
'Misty water coloured memories' - of 60 pence for one.

Crumbs 10.39 - thanks too. One of many possible scenarios . . . Go Scancell !

. . . links to an 'In Vivo' article from July 18 by the unfortunate William Looney - yep !

''Strong foundational research in immunology and some promising early phase trial results have so far failed to expedite the validation of vaccines to treat cancer'' . . . ''The arrival of immunotherapy as a fourth weapon in the armamentarium against cancer – following on the traditional mainstays of surgery, chemotherapy and radiation – has brought fresh attention to the role that vaccines can play in stimulating the body’s natural defenses against the abnormal cell growth that leads to malignancies''.

''Dr. Catherine Wu, a leader in cancer vaccine research with affiliations to the Dana-Farber Cancer Institute (DFCI), the Broad Institute and Harvard Medical School, notes that researchers face complexities in designing even the simplest vaccines. Wu and many other cancer researchers interviewed by In Vivo believe that the fallow period in vaccines discovery may finally be coming to an end, for two reasons. The first is improved understanding of how to target a critical immunologic defense mechanism, the PD-1 checkpoint blockade, that attaches and neutralizes a crucial protein that cancer cells rely on to confuse and counter attacks from the immune system’s “helper” T-cells.

(Exhibit 1 - Therapeutic Cancer Vaccines In Active Clinical Trials - 25 are listed).

And BTW not a single mention of Scancell throughout !

Lets hope Dr Wu is right - ''Wu . . . believe(s) that the fallow period in vaccines discovery may finally be coming to an end''. Me Too ! Me Too !

https://invivo.pharmaintelligence.informa.com/IV005362/Cancer-Vaccines-Is-There-A-Future-Beyond-Trial-And-Error

I need cheering up - ''in the corners of my mind, misty water colour memories'' - of 60 pence !

''Can it be that it was all so simple then ?''

https://uk.video.search.yahoo.com/search/video?fr=yfp-t-m&p=barbra+streisand+memories+youtube#id=4&vid=0a00ef61fd5e1eaa80e4a8f3c85569b8&action=click

Jason Luke figures in this cautionary piece - where have we heard his name before ?

https://www.nature.com/articles/d41586-018-07445-3?utm_source=briefing-dy&utm_medium=email&utm_campaign=briefing&utm_content=20181119

The recording of Cliff Holloway's presentation last week :-

https://www.youtube.com/watch?v=nKd_cDot6cw

The recording of Cliff Holloway's presentation last week :-

https://www.youtube.com/watch?v=nKd_cDot6cw

Mon 22.17 - I like your 'pondering' in the 2nd para. - JP Morgan and all. Of course, you could be right ! Waiting for a 'left field' announcement then.

Mon 23.01 re C7 - I echo your words to C7 and would only add that 'plenty' will actually be 'all' - ''wish you (C7) well and be rooting for you.'' Good Luck Puncher . . .

''Announcement made last week that Cornelis Melief, CSO/founder of Isa Pharmaceuticals and member of LD's CRUK Grand Challenge Team has been awarded the 2018 ESMO Immuno-Oncology Award this week - pretty big deal for him and Isa and will do no harm to the Grand Challenge team's chances of success. Also of course, Scancell licensed Isa's Amplivant technology as the adjuvant for Modi1.''

https://www.esmo.org/Press-Office/Press-Releases/immuno-oncology-award-cornelis-melief